Adalimumab for the treatment of Crohn's disease.
BACKGROUND
Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing-remitting course with trans-mural inflammation of potentially any section of the digestive tract. Adalimumab (ADA) is a subcutaneously administered, recombinant, fully human, IgG1 monoclonal antibody that binds with high affinity and specificity to human TNF-alpha, thus modulating its biologic functions and its proinflammatory effects.


OBJECTIVE
To review the available data on ADA in CD for biological properties, efficacy, and safety.


METHODS
Electronic searches were conducted using the Pubmed and SCOPUS databases from the earliest records to April 2008. The search terms used were "adalimumab", "anti-TNF", "TNF-alpha", "biologicals", "inflammatory bowel disease", and "Crohn's disease". Reference lists of all relevant articles were searched for further studies.


RESULTS
Available studies suggest that ADA has the potential to induce and maintain clinical response and remission in moderate-severe CD, both in anti-TNF-naïve patients and in subjects who lost their response and/or became intolerant to infliximab (IFX). ADA seems also effective in maintaining corticosteroid-free remission and obtaining complete fistula closure (although no specific randomized trials are available). No concomitant immunosuppressors seem to be necessary. Side effects appear similar to IFX, while site-injection reactions are frequent and specific. Data on immunogenicity and its clinical impact are uncertain.


CONCLUSIONS
ADA appears to be effective in inducing and maintain clinical remission in CD, including patients not manageable with IFX. Successive clinical practice and further on going trials will confirm a positive role for ADA as a new anti-TNF treatment in CD. The impact on clinical management or on resources should be more studied.
Cassinotti
Andrea
A
Department of Clinical Sciences, Chair of Gastroenterology, "Luigi Sacco" University Hospital, Milan, Italy.
Ardizzone
Sandro
S
Porro
Gabriele Bianchi
GB
Inflamm Bowel Dis. 2007 Nov;13(11):1323-32
17636564
J Pharmacol Exp Ther. 2002 May;301(2):418-26
11961039
J Rheumatol. 2003 Dec;30(12):2563-71
14719195
Drugs. 2005;65(16):2253-86
16266194
Arthritis Rheum. 2008 May;58(5):1248-57
18438840
Expert Opin Drug Saf. 2005 Jul;4(4):637-41
16011443
Adv Exp Med Biol. 1995;371B:821-4
7502905
Ann Intern Med. 2003 May 20;138(10):807-11
12755552
Gastroenterology. 1976 Mar;70(3):439-44
1248701
Gut. 2008 Apr;57(4):559; author reply 559-60
18334664
Gastroenterology. 2007 Jan;132(1):52-65
17241859
Medicine (Baltimore). 2007 Jul;86(4):242-251
17632266
Lancet. 2007 May 12;369(9573):1627-40
17499605
Aliment Pharmacol Ther. 2007 Dec;26(11-12):1509-20
17931345
Lancet. 1992 Jan 11;339(8785):89-91
1345871
Pharmacol Ther. 2008 Feb;117(2):244-79
18155297
Am J Gastroenterol. 2004 Oct;99(10):1984-9
15447761
Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18
17269996
Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):12-8
15852249
Clin Gastroenterol Hepatol. 2004 Jul;2(7):542-53
15224278
Am J Gastroenterol. 2005 Jan;100(1):75-9
15654784
Lancet. 2000 Feb 26;355(9205):735-40
10703815
Lancet. 2007 May 12;369(9573):1641-57
17499606
Clin Exp Immunol. 1993 Oct;94(1):174-81
8403503
N Engl J Med. 2003 Feb 13;348(7):601-8
12584368
Drugs. 2007;67(17):2511-37
18034589
JAMA. 2006 May 17;295(19):2275-85
16705109
Gut. 2006 Mar;55 Suppl 1:i16-35
16481629
J Infect Dis. 2006 Aug 15;194(4):486-92
16845632
Anal Biochem. 2001 Dec 15;299(2):119-29
11730333
Inflamm Bowel Dis. 2004 Jul;10(4):333-8
15475739
Aliment Pharmacol Ther. 2007 Apr 1;25(7):787-96
17373917
Dig Dis Sci. 2006 Nov;51(11):2045-7
17009112
Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):19-22
15852250
Ann Intern Med. 2007 Jun 19;146(12):888-90
17577009
Gastroenterology. 2007 Jul;133(1):137-49
17631138
Gastroenterology. 2006 Feb;130(2):323-33; quiz 591
16472588
J Pediatr Gastroenterol Nutr. 2008 Feb;46(2):208-11
18223382
J Inherit Metab Dis. 2008 Dec;31 Suppl 3:505-9
18172743
Gut. 2005 Jun;54(6):890
15888806
Gastroenterology. 2000 Oct;119(4):1148-57
11040201
Arthritis Rheum. 2004 May;50(5):1690-2
15146441
Ann Intern Med. 2007 Jun 19;146(12):829-38
17470824
Ann Rheum Dis. 2006 Jul;65(7):889-94
16439435
Gut. 2008 Feb;57(2):211-7
17895357
Eur J Gastroenterol Hepatol. 2004 Jun;16(6):627-30
15167167
Ann Rheum Dis. 2006 Jun;65(6):839-40
16699060
Inflamm Bowel Dis. 2006 Jan;12(1):22-8
16374254
Inflamm Bowel Dis. 2006 Aug;12(8):827-8
16917239
Aliment Pharmacol Ther. 2008 Feb 15;27(4):308-15
18081730
Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8
15691299
Clin Exp Immunol. 2005 Aug;141(2):372-80
15996202
Gastroenterology. 2003 Apr;124(4):917-24
12671888
Gut. 2007 Sep;56(9):1232-9
17299059
J Rheumatol. 2007 Feb;34(2):272-9
17304653
Gut. 1993 Dec;34(12):1705-9
8031350
J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):357-9
16131995
Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80
17311600
J Intern Med. 2002 Dec;252(6):475-96
12472908
BioDrugs. 2007;21(2):125-32; discussion 133-4
17402796